What is Onc.AI?
Onc.AI operates at the intersection of oncology, computer vision, and predictive analytics. The company is dedicated to building a comprehensive pipeline of physician-centered products designed to fulfill the potential of precision medicine. By utilizing a rapidly growing, proprietary dataset, Onc.AI empowers clinicians with AI-driven tools that interpret medical imaging and patient data with unprecedented accuracy. Their multidisciplinary team, comprised of seasoned entrepreneurs, scientists, and software engineers, focuses on bridging the gap between raw data and clinical decision support, ultimately aiming to improve the standard of care for cancer patients globally.
How much funding has Onc.AI raised?
Onc.AI has raised a total of $31M across 2 funding rounds:
Unspecified
$6M
Series A
$25M
Unspecified (2020): $6M with participation from KdT Ventures, Digitalis Ventures, The Blue Venture Fund, and Accomplice
Series A (2023): $25M led by Digitalis Ventures, The Blue Venture Fund, MassMutual, Action Potential Venture Capital, and Accomplice
Key Investors in Onc.AI
Digitalis Ventures
A venture firm that engineers solutions to unmet needs in health by leveraging deep technical and domain expertise in biotechnology.
The Blue Venture Fund
A strategic partnership among Blue Cross Blue Shield companies focused on advancing healthcare technology, services, and clinical sciences.
MassMutual
A prominent mutual insurance company providing comprehensive financial solutions, wealth management, and strategic investment capital for businesses.
What's next for Onc.AI?
With the recent influx of capital, Onc.AI is poised to scale its enterprise software offerings and expand its clinical validation efforts. The strategic focus will likely shift toward deepening partnerships with healthcare providers and payors, ensuring that their predictive models are seamlessly integrated into existing clinical workflows. As the company matures, the emphasis will remain on refining its multimodal AI capabilities to address the most pressing challenges in oncology, potentially setting a new benchmark for technology-enabled precision medicine in the coming years.
See full Onc.AI company page
